Individuals with Down syndrome have a low risk for many solid tumors, prompting the search for tumor suppressor genes on human chromosome 21 (HSA21). We aimed to identify and explore potential mechanisms of tumor suppressors on HSA21 in hepatocellular carcinoma (HCC). METHODS: We compared expression of HSA21 genes in 14 pairs of primary HCC and adjacent noncancer liver tissues using the Affymetrix HG-U133 Plus 2.0 array (Affymetrix, Santa Clara, CA). HCC tissues and adjacent normal liver tissues were collected from 108 patients at a hospital in China for real-time polymerase chain reaction and immunohistochemical analyses; expression levels of regulator of calcineurin 1 (RCAN1) isoform 4 (RCAN1.4) were associated with clinical features. We overexpressed RCAN1.4 from lentiviral vectors in MHCC97H and HCCLM3 cells and knocked expression down using small interfering RNAs in SMMC7721 and Huh7 cells. Cells were analyzed in proliferation, migration, and invasion assays. HCC cells that overexpressed RCAN1.4 or with RCAN1.4 knockdown were injected into livers or tail veins of nude mice; tumor growth and numbers of lung metastases were quantified. We performed bisulfite pyrosequencing and methylation-specific polymerase chain reaction analyses to analyze CpG island methylation. We measured phosphatase activity of calcineurin in HCC cells. RESULTS: RCAN1.4 mRNA and protein levels were significantly decreased in primary HCC compared with adjacent noncancer liver tissues. Reduced levels of RCAN1.4 mRNA were significantly associated with advanced tumor stages, poor differentiation, larger tumor size, and vascular invasion. KaplanMeier survival analysis showed that patients with HCCs with lower levels of RCAN1.4 mRNA had shorter time of overall survival and time to recurrence than patients whose tumors had high levels of RCAN1.4 mRNA. In HCC cell lines, expression of RCAN1.4 significantly reduced proliferation, migration, and invasive activity. HCC cells that overexpressed RCAN1.4 formed smaller xenograft tumors, with fewer metastases and blood vessels, than control HCC cells. In HCC cells, RCAN1.4 inhibited expression of insulin-like growth factor 1 and vascular endothelial growth factor A by reducing calcineurin activity and blocking nuclear translocation of nuclear factor of activated T cells (NFAT1). HCC cells incubated with the calcineurin inhibitor cyclosporin A had decreased nuclear level of NFAT1. HCC cells had hypermethylation of a CpG island in the 5' regulatory region of RCAN1.4, which reduced its expression. CONCLUSIONS: RCAN1.4 is down-regulated in HCC tissues, compared with non-tumor liver tissues. RCAN1.4 prevents cell proliferation, migration, and invasion in vitro; overexpressed RCAN1.4 in HCC cells prevents growth, angiogenesis, and metastases of xenograft tumors by inhibiting calcineurin activity and nuclear translocation of NFAT1.
BACKGROUND & AIMS:
Individuals with Down syndrome have a low risk for many solid tumors, prompting the search for tumor suppressor genes on human chromosome 21 (HSA21). We aimed to identify and explore potential mechanisms of tumor suppressors on HSA21 in hepatocellular carcinoma (HCC). METHODS: We compared expression of HSA21 genes in 14 pairs of primary HCC and adjacent noncancer liver tissues using the Affymetrix HG-U133 Plus 2.0 array (Affymetrix, Santa Clara, CA). HCC tissues and adjacent normal liver tissues were collected from 108 patients at a hospital in China for real-time polymerase chain reaction and immunohistochemical analyses; expression levels of regulator of calcineurin 1 (RCAN1) isoform 4 (RCAN1.4) were associated with clinical features. We overexpressed RCAN1.4 from lentiviral vectors in MHCC97H and HCCLM3 cells and knocked expression down using small interfering RNAs in SMMC7721 and Huh7 cells. Cells were analyzed in proliferation, migration, and invasion assays. HCC cells that overexpressed RCAN1.4 or with RCAN1.4 knockdown were injected into livers or tail veins of nude mice; tumor growth and numbers of lung metastases were quantified. We performed bisulfite pyrosequencing and methylation-specific polymerase chain reaction analyses to analyze CpG island methylation. We measured phosphatase activity of calcineurin in HCC cells. RESULTS: RCAN1.4 mRNA and protein levels were significantly decreased in primary HCC compared with adjacent noncancer liver tissues. Reduced levels of RCAN1.4 mRNA were significantly associated with advanced tumor stages, poor differentiation, larger tumor size, and vascular invasion. KaplanMeier survival analysis showed that patients with HCCs with lower levels of RCAN1.4 mRNA had shorter time of overall survival and time to recurrence than patients whose tumors had high levels of RCAN1.4 mRNA. In HCC cell lines, expression of RCAN1.4 significantly reduced proliferation, migration, and invasive activity. HCC cells that overexpressed RCAN1.4 formed smaller xenograft tumors, with fewer metastases and blood vessels, than control HCC cells. In HCC cells, RCAN1.4 inhibited expression of insulin-like growth factor 1 and vascular endothelial growth factor A by reducing calcineurin activity and blocking nuclear translocation of nuclear factor of activated T cells (NFAT1). HCC cells incubated with the calcineurin inhibitor cyclosporin A had decreased nuclear level of NFAT1. HCC cells had hypermethylation of a CpG island in the 5' regulatory region of RCAN1.4, which reduced its expression. CONCLUSIONS: RCAN1.4 is down-regulated in HCC tissues, compared with non-tumor liver tissues. RCAN1.4 prevents cell proliferation, migration, and invasion in vitro; overexpressed RCAN1.4 in HCC cells prevents growth, angiogenesis, and metastases of xenograft tumors by inhibiting calcineurin activity and nuclear translocation of NFAT1.
Keywords: IGF1; VEGFA; Liver Cancer; Tumor Suppressor. H epatocellular carcinoma (HCC) is 1 of the most common solid tumors worldwide and has an extremely poor prognosis. Because of the rapid progression of HCC, most patients with this disease are diagnosed at advanced stage. In advanced HCC cases, the 5-year survival rate is as low as 25%-39%, and the recurrence rate is approximately 80%. 1 Unfortunately, sorafenib is the only clinically approved systemic drug for the treatment of patients with advanced HCC, with a partial response of only 2.2% and median overall survival (OS) of 9.2 months.
Although several novel drugs targeting signaling cascades involved in HCC progression have been explored, none has any positive clinical results. 3 Therefore, novel causative genes and molecular pathways underlying HCC progression and metastasis need to be identified and validated. However, the molecular events underlying HCC progression remain largely unknown.
Over the past few years, a series of molecular biomarkers with potential prognostic and therapeutic significance for HCC have been identified. 4, 5 Epidemiologic studies have demonstrated reduced incidence and mortality for many types of solid tumors in individuals with Down syndrome. 6, 7 This observation has prompted the search for tumor suppressor genes located on chromosome 21 (HSA21). 8 We sought to identify novel tumor suppressors of HCC accordingly.
We conducted genome-wide analyses to determine the genes differentially expressed between tumor tissues and adjacent noncancerous liver tissues in 14 patients with HCC. Differential HSA21 genes were analyzed and regulator of calcineurin 1 (RCAN1) was identified as the most downregulated HSA21 gene in patients with HCC. RCAN1 has a wide range of biological roles, including protecting against calcium-mediated oxidative stress, 9 cardiac hypertrophy, 10 VEGF-mediated signaling during angiogenesis, 11 and the formation of aggresomes in Alzheimer's disease. 12 However, knowledge of the function of RCAN1 in tumor development is limited. Previous studies have demonstrated that dysregulation of RCAN1 in vascular endothelium cells contributes to broad cancer protection by inhibiting the formation of an effective tumor vasculature via inhibition of the calcineurin pathway. 13, 14 Yet, the function of RCAN1 in tumor cells remains largely unknown. Here, we demonstrate for the first time that RCAN1 isoform 4 (RCAN1.4) acts as a novel suppressor of HCC through regulation of the calcineurin-nuclear factor of activated T cells pathway.
Materials and Methods

Clinical Specimens
Fresh human HCC tissues and adjacent noncancerous liver tissues for real-time polymerase chain reaction (PCR) (n¼108), western blot (n¼8), and immunohistochemistry (IHC) RNA-seq data of 121 HCC tumor tissues and/or 50 adjacent non-tumor tissues were obtained from The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov). Clinical data of patients with HCC from TCGA were analyzed using a KaplanMeier survival plot.
Microarray Analysis
Total RNA was isolated and purified from 14 pairs of HCC and adjacent noncancerous liver tissues using TRIzol reagent (Invitrogen, Carlsbad, CA) and the RNeasy mini kit (Qiagen, Valencia, CA) according to the manufacturers' protocols. Five micrograms of total RNA from each sample was used to synthesize double-stranded complementary DNA (cDNA), and then amplified and labeled with biotin and hybridized to the GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA) following the procedure outlined in the Affymetrix technical manual. The clinicopathologic characteristics of the 14 patients with HCC are shown in Supplementary Table 1 .
IHC
Tissue microarrays were constructed by Shanghai Biochip Co, Ltd (Shanghai, China). IHC was performed and integrated optical density measured as reported previously. 15 Briefly, staining was assessed based on the percentage of positively stained cells and the staining intensity analyzed by Image-Pro Plus 6.0 (Media Cybernetics, Inc., Bethesda, MD).
Results
Identification of RCAN1.4 as a Candidate Tumor Suppressor in HCC
Comparing gene expression in 14 pairs of cancerous and noncancerous tissues from patients with HCC (GEO Submission: GSE84402) revealed 2320 dysregulated genes (fold change > 2.0 or fold change < -2.0, q value < 0.05), 41 .4% of which were upregulated and 58.6% down-regulated in HCC tissues ( Figure 1A ). Fifteen dysregulated genes on HSA21 were identified (fold change > 2.0 or fold change < -2.0, q value < 0.05; Figure 1B ), 11 of which were down-regulated and 4 upregulated in HCC tissues (Supplementary Table 2 ). RCAN1 was the most significantly down-regulated HSA21 gene ( Figure 1B ).
EDITOR'S NOTES
BACKGROUND AND CONTEXT
Individuals with Down syndrome have a low risk for many solid tumors. This observation has prompted the search for tumor suppressors located on chromosome 21 (HSA21) in HCC.
NEW FINDINGS
This study shows that HSA21 gene RCAN1.4 acts as a potent tumor suppressor of HCC that attenuates tumor progression and angiogenesis via the inhibition of CaN-NFAT1 signaling.
LIMITATIONS
Further studies are needed to explore calcineurinindependent mechanisms by which RCAN1.4 exerts its suppressive effects on HCC.
IMPACT
The findings indicate RCAN1.4 acts as a novel suppressor of HCC. RCAN1.4 and its related signaling represent a novel therapeutic target in HCC.
We also analyzed the dysregulated genes located on HSA21 in the TCGA cohort (n¼50). Similarly, RCAN1 was 1 of the most significantly down-regulated HSA21 genes (Supplementary Table 3 ). In addition, the Oncomine database (www.oncomine.com) showed that RCAN1 was decreased in most types of solid tumors, including breast, colorectal, pancreatic, and liver cancer (Supplementary Figure 1) . Only 3 transcripts (RCAN1.1, RCAN1.2, and RCAN1.4) were reported to be detected in human tissues. 16 Therefore, we detected the 3 RCAN1 transcripts in 108 pairs of HCC and adjacent noncancerous liver tissues using real-time PCR. Transcript RCAN1.4 was significantly decreased in HCC tissues compared with their corresponding noncancerous liver tissues (88.9%, Figure 1C and Supplementary Figure 2A) . However, the other 2 transcripts, RCAN1.1 and RCAN1.2, were found at very low abundance and exhibited no significant difference ( Figure 1C ). Down-regulation of RCAN1.4 was further confirmed by Western blot (Supplementary Figure 2B ) and IHC analyses (Supplementary Figure 2C) . In addition, RCAN1 was decreased in different HCC subtypes in the TCGA cohort (Supplementary Figure 2D) , indicating that down-regulation of RCAN1 is a common event in HCC.
Clinical association studies found that down-regulation of RCAN1.4 mRNA was significantly associated with advanced TNM stages (P ¼ .008), poor differentiation (P ¼ .034), larger tumor size (P ¼ .019), and vascular invasion (P ¼ .012) (Supplementary Table 4 ). Comparing RCAN1.4 expression between patients with HCC with and without relapse, we found that RCAN1.4 was decreased in relapsed patients ( Figure 1C ). Kaplan-Meier survival analysis showed that patients with HCC with low RCAN1.4 mRNA levels had worse OS and shorter recurrence time (TTR) than those with high RCAN1.4 mRNA levels ( Figure 1D ). However, RCAN1.1 and RCAN1.2 mRNA levels had no significant effect on the OS and TTR of patients with HCC ( Supplementary Figure 3) . IHC analysis confirmed that patients with HCC in the low RCAN1.4 expression group exhibited worse OS and shorter TTR than those in the high RCAN1.4 expression group in another cohort containing 196 patients with HCC ( Figure 1E ). Down-regulation of RCAN1.4 correlated with larger tumor size (P ¼ .032) and vascular invasion (P ¼ .029) in this cohort (Supplementary Table 5 ). Cox's multivariate analysis showed that RCAN1.4 was an independent predictor of postoperative OS and TTR (Supplementary Table 6 ). Similar results were observed in the TCGA cohort ( Figure 1F ). Taken together, these findings suggest that down-regulation of RCAN1.4 may contribute to metastasis and malignant progression of HCC. Figure 6) , whereas knockdown of RCAN1.4 significantly promoted the proliferation, migration, and invasion of HCC cells in vitro (Figure 2A-B) . Similarly, transient knockdown of RCAN1.4 using siRNAs also increased the proliferation, migration, and invasion of HCC cells in vitro (Supplementary Figure 7) . The tumor suppressive function of RCAN1.4 was verified using the CRISPR-Cas9 system. Knocking out of RCAN1.4 markedly promoted the proliferation, migration, and invasion of HCC cells in vitro (Supplementary Figure 8) . Moreover, stable overexpression of RCAN1.4 significantly reduced the size of HCC tumors in the orthotopic liver compared with the control group in vivo ( Figure 2C ), as well as the number of lung metastatic nodules ( Figure 2D ). In contrast, knockdown of RCAN1.4 significantly increased the number of metastatic lung nodules when HCC cells were injected into the lateral tail vein of nude mice ( Figure 2E ). Accordingly, knockdown of RCAN1.4 decreased the OS of nude mice in vivo ( Figure 2F ).
To investigate the role of RCAN1.4 in the early stages of hepatocarcinogenesis, we knocked down the expression of RCAN1.4 in a non-transformed hepatic cell line (L02) and performed soft agar colony formation assay. RCAN1. Table 7) . Taken together, these results suggest that RCAN1.4 acts as an important tumor suppressor in HCC progression and metastasis.
RCAN1.4 Performed as an Endogenous Inhibitor of Calcineurin-NFAT1 Signaling in HCC
RCAN1 has been reported to specifically block calcineurin-mediated nuclear factor of activated T cells (NFAT) nuclear localization and transcriptional activity. 17, 18 Therefore, we measured the phosphatase activity of calcineurin in HCC cells after stable overexpression or knockdown of RCAN1.4. Calcineurin activity was significantly reduced when RCAN1.4 was overexpressed, while increased when RCAN1.4 was knocked down in HCC cells ( Figure 3A ). The nuclear distribution status of NFAT subtypes (NFAT1-4) was evaluated by Western blot. Analysis of nuclear and cytoplasmic extracts showed that overexpression of RCAN1.4 blocked nuclear accumulation of NFAT1, whereas knockdown of RCAN1.4 promoted nuclear accumulation of NFAT1 in HCC cells ( Figure 3B and Supplementary Figure 10A ). The negative regulation of NFAT1 nuclear translocation by RCAN1.4 was further confirmed by immunofluorescence ( Figure 3C ). However, total NFAT1 expression levels were not affected by RCAN1.4 (Supplementary Figure 10B) , suggesting that changes in the nuclear level of NFAT1 is not the result of a change in total NFAT1 expression. Interestingly, nuclear translocation of other NFAT subtypes (NFAT2-4) was not altered consistently ( Figure 3B and Supplementary Figure 10A) .
Next, we treated HCC cells with cyclosporin A (CsA), a calcineurin inhibitor, and analyzed the nuclear level of NFAT1. CsA treatment reversed nuclear accumulation of NFAT1 in HCC cells, which was upregulated by RCAN1.4 knockdown ( Figure 3D ), indicating that RCAN1.4 regulated nuclear localization of NFAT1 by inhibiting calcineurin activity. To further confirm the role of RCAN1.4 in the regulation of calcineurin-NFAT1 signaling, a constitutively active form of calcineurin A (CnAd) and a phosphatase dead mutant of calcineurin A (CnAd-H151A) were transfected into HCC cells which were stably over-expressing RCAN1.4. The RCAN1.4-mediated repression of NFAT1 nuclear translocation was recovered by CnAd, but not by CnAd-H151A ( Figure 3D ). Dephosphorylation in the regulatory domain of NFAT1 by calcineurin is required for its nuclear translocation and transcriptional activity. 19 We found that RCAN1.4 could negatively regulate NFAT1 phosphorylation at Ser326, while phosphorylation of Ser326 represent the inactive form of NFAT1 (Supplementary Figure 10B) . Tumor tissues from orthotopic tumor implantation models were evaluated for NFAT1 by IHC. Much weaker nuclear staining of NFAT1 was observed in RCAN1.4-overexpression groups compared with control groups (Supplementary Figure 11A) . We further analyzed the associations between RCAN1.4 expression and nuclear level of NFAT1 in 196 HCC samples. Consistently, RCAN1.4 expression significantly negatively correlated with the nuclear level of NFAT1 (Supplementary Figure 11B-C) . Thus, RCAN1.4 negatively regulates NFAT1 nuclear translocation and NFAT1 activity through inhibition of calcineurin activity in HCC.
To investigate the possible role of calcineurin-NFAT1 signaling in RCAN1.4-mediated tumor progression, HCC cells were transfected with a set of siRNAs to silence calcineurin and NFAT1 expression (Supplementary Figure 12) . Functional assays showed that silencing of calcineurin or NFAT1 specifically reversed the proliferation, migration, and invasive activity of HCC cells, which were enhanced by RCAN1.4 knockdown ( Figure 3E ). Furthermore, CsA treatment significantly decreased the number of lung metastatic nodules in RCAN1.4-knockdown groups but not the control groups ( Figure 3F ). Taken together, these results suggest that RCAN1.4 involves in HCC progression by acting as an endogenous inhibitor of calcineurin-NFAT signaling.
Insulin-like growth factor 1, a Direct Transcriptional Target of NFAT1, was Essential for RCAN1.4-Mediated HCC Progression
Next, we explored downstream targets of RCAN1.4 using tumor associated PCR array. Eight genes were significantly altered after RCAN1.4 knockdown in SMMC7721 cells (fold change > 2.0 or fold change < -2.0; Figure 4A and Supplementary Table 8 ). However, only insulin-like growth factor 1 (IGF1) and vascular endothelial growth factor A (VEGFA) could be rapidly rescued by further silencing of NFAT1 expression (Supplementary Figure 13 ), indicating that they may be the direct transcriptional targets of NFAT1. Furthermore, knockdown of RCAN1.4 increased IGF1 levels in the culture supernatant of HCC cells ( Figure 4B ). In contrast, overexpression of RCAN1.4 decreased IGF1 mRNA levels in HCC cells and protein levels in the culture supernatant of HCC cells (Supplementary Figure 14) . When further silencing NFAT1 expression, IGF1 levels in the culture supernatant were significantly reversed for HCC cells in which RCAN1.4 was stably knocked down ( Figure 4B ). Sequence analysis revealed 4 putative NFAT1 binding sites in the IGF1 promoter. Serial deletion showed that the second and third NFAT1 binding sites were critical for NFAT1-induced IGF1 transactivation ( Figure 4C ). ChIP, chromatin immunoprecipitation (ChIP) assay confirmed that NFAT1 directly bound the second and third NFAT1 binding sites in the IGF1 promoter in HCC cells ( Figure 4D ).
The correlation between IGF1 expression and nuclear level of NFAT1 was further confirmed in 196 HCC samples. Consistently, IGF1 expression was significantly positively correlated with the nuclear level of NFAT1 (Supplementary Figure 15A -B). These results suggest that NFAT1 directly transactivates IGF1 expression in HCC.
To explore the role of IGF1 in RCAN1.4-mediated HCC progression, HCC cells with RCAN1.4 stably knocked down Representative images of lung tissues from nude mice. C, cancer site (40X magnification, scale bar¼200 mm). All data are shown as the mean±SEM of 3 independent experiments. *P < .05, **P < .01, ***P < .001.
activation of the ERK/MAPK pathway and, subsequently, promoted the proliferation and migration of HCC cells. 20 Here, we found that overexpression of RCAN1.4 extensively decreased the levels of p-IGF1R, p-Raf, p-MEK1/2, p-ERK1/2, and MMP9 in HCC cells (Supplementary Figure 18A) . In contrast, RCAN1.4 knockdown increased the levels of these proteins (Supplementary Figure 18B) . Pretreatment with anti-IGF1R blocking antibody or IGF1R inhibitor (NVP-AEW541) reversed the levels of these proteins (Supplementary Figure 18B) . To confirm the role of MMP9 in RCAN1.4-mediated HCC progression, HCC cells in which RCAN1.4 was stably knocked down were transfected with MMP9 siRNAs (Supplementary Figure 19A) . MMP9 silencing could significantly attenuate the migration and invasion of HCC cells, antagonizing the effects of RCAN1.4 knockdown (Supplementary Figure 19B-C) . The levels of p-IGF1R, p-Raf, p-MEK1/2, p-ERK1/2, and MMP9 were also analyzed in orthotopic HCC implantation models. The expression levels of these proteins were decreased in RCAN1.4-overexpression groups compared with control groups (Supplementary Figure 20) . Taken together, we concluded that RCAN1.4 decreased IGF1 autocrine through regulation of the calcineurin/NFAT1 pathway, which then influenced IGF1R/ERK/ MAPK signaling and MMP9 expression.
RCAN1.4 Negatively Regulated VEGFA Expression was Associated With Angiogenesis in HCC
We also determined whether VEGFA is another direct transcriptional target of NFAT1. Sequence analysis revealed 2 putative NFAT1 binding sites in the VEGFA promoter. Serial deletion showed that the second NFAT1 binding site was critical for NFAT1-induced VEGFA transactivation ( Figure 5A ). ChIP assay further confirmed that NFAT1 directly bound the second NFAT1 binding site in the VEGFA promoter in HCC cells ( Figure 5B ). VEGFA is a potent inducer of angiogenesis in solid tumors. Conditioned medium (CM) from HCC cells that stably overexpressed RCAN1.4 reduced the proliferation and migration of human umbilical vein endothelial cells (HUVECs) in vitro when compared with the control CM (Supplementary Figure 21) . In addition, knocking down endogenous RCAN1.4 in HCC cells enhanced HUVEC proliferation and migration, which could be significantly blocked by VEGFA neutralization ( Figure 5CD ). Moreover, a marked decrease in microvascular density (MVD) was observed in tumor tissues from in vivo models overexpressing RCAN1.4 ( Figure 5E ). We analyzed the associations between RCAN1.4 protein levels and MVD in tumor tissues from 196 patients with HCC. Consistently, RCAN1.4 expression significantly negatively correlated with MVD ( Figure 5F ). These data indicate that RCAN1.4-dependent VEGFA expression influences angiogenesis in human HCC.
Aberrant CpG Methylation Reduced RCAN1.4 Expression
Aberrant hypermethylation of cytosine-phosphatidylguanosine (CpG) islands (CGIs) in the 5 0 regulatory region is a major cause of tumor suppressor silencing in cancer. To determine whether RCAN1.4 down-regulation is associated with DNA methylation in HCC, liver cancer cells with relatively low levels of RCAN1.4 expression were treated with varying concentrations of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-Aza-dC). Treatment of HCC cells with 5-Aza-dC led to a dose-dependent restoration of RCAN1.4 expression, suggesting a negative correlation between DNA methylation and RCAN1.4 expression ( Figure 6A ). To confirm this finding, we scanned the 5 0 regulatory region of RCAN1.4 for CGIs. A distinct CGI was identified in the first intron ( Figure 6B ). Next, we performed bisulfite sequencing to investigate methylation status in 14 pairs of primary HCC and adjacent liver samples. Highly methylated CGI regions were found in the first intron (Region 2: þ1608/þ1632; Region 3: þ1719/þ1767) in HCC, whereas significantly lower levels of methylation were found in the adjacent liver tissues ( Figure 6C ). However, no difference was found in the methylation status of a CpG dinucleotide-rich region (Region 1:-140/-146) in the RCAN1.4 promoter ( Figure 6C ). Methylation-specific PCR of the CGI region validated this finding ( Figure 6D ). Taken together, these data indicate that the down-regulation of RCAN1.4 in HCC is attributed to hypermethylation of the 5'-downstream region of the RCAN1.4 promoter.
Discussion
Down syndrome, also known as trisomy 21, is most commonly caused by the duplication of one of the copies of chromosome 21. Numerous epidemiologic studies have shown that solid tumors are reduced in Down syndrome, 6, 7, 21 , leading to the speculation of possible tumor suppressor genes on chromosome 21. Based on large-scale studies, HSA21 is currently estimated to comprise 534 genes that account for 2176 gene transcripts. 22 Our genome-wide analyses identified RCAN1 as one of the most down-regulated HSA21 genes in patients with HCC. The in vitro and in vivo results in the present study indicate that RCAN1.4 may be an endogenous tumor suppressor of HCC, and that it plays a critical role in the progression and metastasis of HCC. However, the effect of RCAN1.4 on hepatocarcinogenesis needs to be investigated further in other powerful in vivo models, such as the transposon-based mouse model, 23 which can efficiently identify and validate candidate genetic drivers of HCC in vivo. 24 The human RCAN1 gene comprises 7 exons separated by 6 introns. Four transcripts sharing the common sequence from exon 5 to exon 7 with an alternative first exon (exon 1, exon 2, exon 3, or exon 4) are predicted to be generated by alternative splicing, resulting in different isoforms with different patterns of expression and regulation. 16 Previous studies have shown that RCAN1 physically and functionally interacts with calcineurin and effectively inhibits its phosphatase activity, which could result in suppressing nuclear translocation of members of the NFAT transcription factor family by preventing their dephosphorylation. 17, 18, 25 Exon 4 gives rise to the 197-amino-acid isoform RCAN1.4, which binds calcineurin at or near the catalytic domain of the CsA treatment specifically decreased the number of lung metastatic nodules of shRCAN1.4 groups. Scale bars¼100 mm. All data are shown as the mean±SEM of 3 independent experiments. *P < .05, **P < .01, ***P < .001. ChIP assay showed an interaction of NFAT1 with 2 potential binding sites in the IGF1 promoter. Real-time PCR was performed to detect the amount of immunoprecipitated product. (E) Growth (left), migration (middle), and invasion (right) of HCC cells were analyzed after transfecting with IGF1 siRNA (siIGF1#1, siIGF1#2, and siIGF1#3) or scramble control siRNA (siControl). All data are shown as the mean±SEM of 3 independent experiments. *P < .05, **P < .01, ***P < .001.
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catalytic A subunit. 25 The primary calcineurin-binding portion of RCAN1.4 is encoded by exon 7, which is common to all RCAN1 isoforms. 18 This region includes 2 independent motifs, ELHA and PxIxxT, that interact with calcineurin. 26 The ELHA motif binds to calcineurin to inhibit it, probably in a broader amino acid context, such as the CIC motif. 27 Two additional sites have been reported for calcineurin interaction; 1 is specific to the N-terminal region of RCAN1.4, and the other is the highly conserved serineproline (SP) motif (known also as a FLISPP motif), acting as competitive inhibitors of calcineurin. 25, 28 When calcineurin is activated by calcium, it dephosphorylates multiple residues in the regulatory domain of NFAT subtypes, leading to their translocation to the nucleus and activation of their transcriptional activity. 29 Here, we demonstrated that overexpression of RCAN1.4 increased the phosphorylation of Ser326 in the regulatory domain of NFAT1, but decreased the nuclear phosphorylation of Ser54. Unlike phosphorylation of Ser326, the phosphorylation of Ser54 in NFAT1 was reported to enhance NFAT transactivation. 19 To further confirm the regulatory role of RCAN1.4 on calcineurin-NFAT signaling, we used CnAd and CnAd-H151A, the latter of which contains a histidine to alanine substitution at residue 151, resulting in a lack of catalytic activity. 30, 31 CnAd, but not CnAd-H151A, was able to restore RCAN1.4-mediated repression of NFAT1 nuclear translocation. Thus, RCAN1.4 can inhibit the phosphatase activity of calcineurin and subsequently block calcineurin-mediated NFAT1 nuclear localization and transcriptional activity in HCC cells.
The calcineurin-NFAT pathway transmits signals to the nucleus from a wide variety of receptors and is vital for Scale bar¼100 mm. All data are shown as the mean±SEM of 3 independent experiments. *P < .05, **P < .01, ***P < .001. many developmental events, such as axon outgrowth, cardiac morphogenesis, lung morphogenesis, neural crest diversification, epithelial stem cell maintenance, and immune responses. 17 Several key findings have pointed to important roles of calcineurin-NFAT signaling in modulating phenotypes associated with malignancy and tumor progression. [32] [33] [34] Recently, the implication of NFAT1 in oncogenic processes has begun to be understood. NFAT1 and its upstream activator calcineurin are essential to the tumorigenic and metastatic properties of breast cancer cells. 29, 34 In addition, the ectopic activation of NFAT1 activates c-Myc, which is a critical transcription factor for pancreatic cancer cell growth in vitro and in vivo. 33 In our study, we found that silencing calcineurin and NFAT1 specifically and effectively reduced proliferation, migration, and invasion of HCC cells in which RCAN1.4 was knocked down, supporting their oncogenic role in RCAN1.4-mediated HCC progression.
Previous studies have shown that the targets of NFAT signaling are mainly cytokines, growth factors, and their receptors, such as IL-2, IL-4, IL-8, MMP3, CCL8, VEGF, and CD40 ligand. 17, 35 We found that NFAT1 directly induces the transcription of IGF1 in HCC cells. IGF1 and IGF1R-mediated signaling plays a critical role in promoting tumor growth and metastasis, 36 maintaining cancer stem cell selfrenewal, 37 and contributing to sorafenib resistance. 38 Our results demonstrate that IGF1 is essential for RCAN1.4-mediated HCC progression by influencing the IGF1R/ERK/ MAPK pathway, which was previously reported to be hyperactivated in human hepatocarcinogenesis. 20 RCAN1 is also known to attenuate endothelial cell proliferation and angiogenesis, 13 , but whether endogenous RCAN1 in tumor cells is also associated with angiogenesis in solid tumors is unclear. Notably, we identified VEGFA as another target of NFAT1 in HCC cells. RCAN1.4 regulated the proliferation and migration of HUVECs in vitro through the inhibition of VEGFA secretion. Our in vivo and clinical data also showed that the expression of RCAN1.4 was negatively associated with MVD, supporting an influence of RCAN1.4 on angiogenesis in HCC via paracrine regulation of VEGFA. Thus, NFAT1-induced cytokines remodeling the tumor microenvironment in both an autocrine and paracrine manner are essential for RCAN1.4-mediated HCC progression.
Most previous studies, as well as our present study, focused on the role of RCAN1.4 in regulating the calcineurin/NFAT pathway. However, an additional calcineurinindependent mechanism may exist in RCAN1.4-mediated functions. One study noted that RCAN1.4 could interact with Raf-1 kinase and participate in Raf-1-mediated intracellular signaling in HUVECs. 39 In lymphoma cells, RCAN1.4 was shown to interact with IkBa and affect its Y42 phosphorylation, finally inhibiting NF-kB signaling activity. 40 It will be interesting to investigate other (calcineurin-independent) mechanisms by which RCAN1.4 exerts its suppressive effects on cancer in future studies. 
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Calcineurin inhibitors, such as tacrolimus and CsA, are the main immunosuppression-based protocols in orthotopic liver transplantation. However, some studies showed that calcineurin inhibitors result in a higher HCC recurrence rate after liver transplantation. 41, 42 The exact mechanism of this increased risk remains to be clarified. One of the prevailing hypothesis is immunosuppressive therapy-induced impairment of the host immune system, impairing both the innate and adaptive immune responses. A dosedependent relationship between calcineurin inhibitors and post-transplant risk of HCC recurrence was observed in a retrospective study. 43 Overexposure to calcineurin inhibitors in clinical practice may be particularly relevant early after liver transplantation, when the immune system should be able to detect and destroy remaining HCC cells in the bloodstream. Another hypothesis is that calcineurin inhibitors activate proto-oncogenes and cancer pathways. 44, 45 However, more and more preclinical data indicate that calcineurin inhibitors have an anti-neoplastic effect, such as inhibiting the growth, invasion, and tumorigenesis of solid tumors, 46, 47 , including HCC. 48 Our metastatic model of nude mice also showed that CsA treatment could significantly decrease the lung metastasis of HCC cells with stable RCAN1.4 knockdown, but had no antimetastatic effect on HCC cells that expressed high level of RCAN1.4. These data suggest that calcineurin inhibitors may have antitumor activity for patients with HCC who had low RCAN1.4 expression or hyperactivation of calcineurin-NFAT1 signaling in tumors.
Supplementary Material
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Supplementary Materials and Methods
Cell Lines
Human HCC cells (HepG2, Hep3B, SK-Hep1, and PLC) were purchased from the American Type Culture Collection. Human HCC cells (MHCC97H, MHCC97L, and HCCLM3) were provided by the Liver Cancer Institute of Zhongshan Hospital of Fudan University (Shanghai, China). MHCC97H, MHCC97L, and HCCLM3 cells are metastatic cell lines with same genetic background but different lung metastatic potentials. Huh7 cells were purchased from Riken Cell Bank (Tsukuba, Japan). SMMC7721, human normal liver cell line L02, and human umbilical cord vein endothelial cells (HUVECs) were purchased from Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China).
Cell Culture
HCC cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Gibco) and incubated at 37 C under a humidified atmosphere with 5% CO 2 . HUVECs were cultured in serum-free medium for endothelial cells (SFM; Invitrogen, Carlsbad, CA), supplemented with 20% FBS, 0.1 mg/ml of heparin, and 0.03 mg/ml of endothelial cell growth supplement (Upstate Biotechnology, Lake Placid, NY). HUVECs at passages 2-7 were used.
Western Blot
Briefly, tissue and cell samples were homogenated in a RIPA buffer (Qiagen, China) with a cocktail of proteinase inhibitors (Roche Applied Science, Switzerland) and a cocktail of phosphatase inhibitors (Roche Applied Science). For preparation of the nuclear protein fraction, the NE-PER Nuclear and Cytoplasmic Protein Extraction Kit (Thermo Fisher Scientific, Rockford, IL) was used according to the manufacturer's instructions. The protein concentrations were determined using the Bicinchoninic Acid (BCA) Kit (Pierce, Rockford, IL). Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). The membranes were incubated with primary antibodies overnight at 4 C and probed with secondary antibodies at room temperature for 1-2 hours. Antibody information was showed in Supplementary Table 9 .
Real-time Polymerase Chain Reaction Assay
Total RNA was extracted from cells and tissues using TRIzol reagent (Invitrogen), and reverse transcription was performed using PrimeScript TM RT Reagent Kit (Takara, Dalian, China) according to the manufacturer's instructions. ). When analyzing the mRNA level of RCAN1.4 in clinical HCC samples (n¼108), the 2 -DCt value 0.0045 was defined as low expression, and >0.0045 as high expression, which divided this HCC cohort into 2 groups. The related primers were listed in Supplementary Table 10 .
Immunohistochemical Score
Semiquantitative scores were used to analyze immunostaining of each HCC case in tissue microarray. Intensity score of staining was categorized into 0 (-), 1 (þ), 2 (þþ), or 3 (þþþ), denoting negative, weak, moderate, or strong staining, respectively. Percentage score of immunostaining was categorized into 0 (0%-5%), 1 (6%-25%), 2 (26%-50%), 3 (51%-75%), or 4 (>76%) on the basis of the percentage of positive cells. Three random microscope fields per tissue were calculated. The sum of intensity and percentage of staining was used as final score of expression level, and determined by the formula: final score ¼ intensity score Â percentage score. The final score of 4 was defined as low expression, and >4 as high expression.
Constructs
The RCAN1.4 ORF sequence (NM_203418.2) was PCR amplified using specific primers and cloned into the lentiviral expression vector pWPXL (Addgene, Cambridge, England) to develop pWPXL-RCAN1.4 recombinant plasmid. To construct shRNAs of RCAN1.4 into shRNA expression vector pGreenPuro (System Biosciences, CA), the target sequences were synthesized and inserted into the vector. The shRNA with a non-targeting sequence was used as a negative control. Lentivirus CRISPR construct targeting RCAN1.4 was made using the LentiCRISPRv2 vector (Addgene Plasmid 52961) following the GeCKO protocol. Briefly, LentiCRISPRv2-RCAN1.4 expression plasmid expressing single-guide RNA targeting exon 4 of RCAN1 gene was generated by annealing and cloning the sgRNA primers (sequences listed in Supplementary Table 10 ). The cDNA fragments of constitutively active form of calcineurin A (CnAd; amino acids 1-368) and phosphatase dead form of calcineurin A (CnAdH151A; amino acids 1-368; histidine to alanine substitution at 151 site) were synthesized and cloned into PCMV6-XL5 (OriGene) using EcoR I and Hind lII sites, respectively. Promoter sequences of IGF1 and VEGFA were amplified through PCR and cloned into luciferase reporter gene vector, pGL3-Basic (Promega, Madison, WI), with Hind III and Sma I restriction sites. Primers used for construction of luciferase reporter vectors containing truncated IGF1 or VEGFA promoter were shown in Supplementary Table 10 .
Lentivirus Production and Cell Transduction
Virus packaging was performed in HEK 293T cells after co-transfection of pWPXL-RCAN1.4 with packaging plasmid psPAX2 (Addgene) and envelope plasmid pMD2.G (Addgene) or co-transfection of pGreenPuro-shRCAN1.4 with packaging plasmid pPACK-GAG, pPACK-REV (System Biosciences) and envelope plasmid pVSV-G (System Biosciences) using Lipofectamine 2000 (Invitrogen). Viruses were harvested 48 h after transfection, and viral titers were determined. Cells ( 1Â10 5 ) including MHCC97H, HCCLM3, SMMC7721, and Huh7 were infected with 1Â10 6 recombinant lentivirus-transducing units in the presence of 6 mg/ml polybrene (Sigma, St. Louis, MO).
For lentiCRISPRv2-RCAN1.4, HEK 293T cells were co-transfected with lentiCRISPRv2-RCAN1.4, packaging vector psPAX2, and envelope vector pMD2.G using Lipofectamine 2000 (Invitrogen). Viral particles were harvested and used to transduce HCC cells after 48 h transfection. Cells were selected in medium supplemented with puromycin and single cell was isolated from lentiCRISPRv2-RCAN1.4 transduced cells. Expression of RCAN1.4 in the cell clones was analyzed by western blot. One cell clone knockout for RCAN1.4 (-/-) was selected for further analysis.
Conditioned Medium (CM) Collection
Tumor cells were seeded into 10 cm dish, and were washed with phosphate-buffered saline (PBS) 3 times after attached to dish. Then, tumor cells were cultured in SFM for 3 days. Following incubation period, CM was collected and centrifuged at 500g to remove detached cells and then centrifuged at 12,000 g to discard cell debris (4 C, 10 min). CM was then stored in aliquots at -80 C until used. Each corresponding well was subsequently trypsinized and the number of live cells was counted to allow appropriate correction of CM loading for cell equivalents.
ELISA Assay
The concentration of human IGF1 in the conditioned media collected in vitro was quantified using an ELISA kit (R&D DG100, R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. The IGF1 concentration was normalized by volume and cell number.
Cell Viability
In vitro proliferation of HCC or HUVECs was measured using Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). According to the manufacturer's instructions, HCC cells or HUVECs were seeded in 96-well plates at 4Â10 3 per well in a final volume of 100 ml. HUVECs and HCC cells were cultured in the CM and DMEM, respectively. Then CCK-8 solution (10 ml) was added into each well, and the absorbance at 450 nm was measured after incubation for 2 h at 37 C to calculate the number of viable cells.
Migration Assay
Cell migration assays were performed using Transwell filter chambers (BD Biosciences, Franklin Lakes, NJ). Cells (5Â10 4 tumor cells or 4Â10 4 HUVECs) in 200 ml serum-free culture medium were seeded in the upper chamber of a transwell and 800 ml medium supplemented with 15% FBS or CM of HCC cells was added to the lower chamber. Cells migrated through the membrane were fixed, stained, and counted under light microscope.
Invasion Assay
Transwell filter chambers (BD Biosciences) coated with Matrigel (BD Biosciences) were utilized to perform in vitro invasion assay. 5Â10 4 cells in 200 ml serum-free DMEM were seeded in the upper chamber of a transwell and 800 ml medium supplemented with 15% FBS was added to the lower chamber. After incubation, cells migrated through the membrane were fixed, stained, and counted under light microscope.
Immunofluorescence
Tumor cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 for 10 min, and then blocked with 5% bovine serum albumin (AMRESCO, Solon, OH). The cells were incubated with the primary NFAT1 antibody (1:100, NOVUS Biologicals Inc, Littleton, CO; NB300-504), overnight at 4 C. After washing with PBS, cells were then incubated with Alexa flour 594 second antibody (Invitrogen) at room temperature for 1 h. Nuclei was stained with DAPI (Sigma) for 5 min. Following a final rinse of 3 times with PBS, the cells were imaged by confocal laser scanning microscopy FluoView FV1000 (Olympus, Tokyo, Japan).
Animal Models
For chemical induction of hepatocarcinogenesis, wildtype mice at postnatal day 14 were injected intraperitoneally with DEN (20 mg/kg, N0258-1G; Sigma-Aldrich), and then weaned and maintained on regular chow food. Livers and tumors were harvested for analysis 9 months after the initial injection. The background of the wild-type mice was C57BL/6J, and mice were obtained from the Jackson Laboratory (Bar Harbor, ME).
For xenograft experiments, 6-to 8-week-old male BALB/c nude mice were used. For orthotopic HCC implantation model, 2Â10 6 tumor cells were suspended in a 40 ml serumfree DMEM/Matrigel (BD Biosciences, Franklin Lakes, NJ) mixture (1:1 volume) for each nude mouse. Through an 8-mm transverse incision made in upper abdomen under anesthesia, each nude mouse was orthotopically inoculated in the left hepatic lobe with a microsyringe. All of mice were sacrificed 6 weeks later. For the lateral tail vein metastasis model, 2Â10
6 tumor cells suspended in 200 ml serum-free DMEM were injected into the lateral tail vein of nude mice. After 6 weeks, all of mice were sacrificed. Tumor volume was calculated as follows: V (volume) ¼ (length Â width 2 )/2. Their lung tissues were dissected and fixed with 4% phosphate-buffered neutral formalin for at least 72 h. Lung tissues were analyzed by H&E staining.
All animals were housed in a virus-free facility and maintained in a temperature and light (12 h light/dark cycle) controlled animal facility. All protocols for animal care and use were approved by the Animal Care Committee of the Shanghai Cancer Institute and were in accordance with regulations for the Administration of Affairs Concerning Experimental Animals and National Institutes of Health Guidelines.
MVD Assessment
The microvessel density (MVD) in tumor tissues, which represents the degree of angiogenesis in vivo or in clinical HCC samples, was evaluated by staining for CD34. Any discrete cluster or single cell stained for CD34 was counted as 1 microvessel. We first scanned the stained microvessels in the 100Â magnification and we chose 3 vascularized areas. Then we counted the microvessels at the magnification of 200Â and the mean microvessels number of these 3 areas were recorded.
Tumor Metastasis PCR Array Analysis
The Tumor Metastasis RT 2 Profiler PCR Array, consisting of 84 genes known to be involved in metastasis, was used to profile SMMC7721-shRCAN1.4 or SMMC7721-shNC cells according to the manufacturer's instructions (Qiagen). Briefly, the procedure began with the conversion of experimental RNA samples into first-strand cDNA using the RT 
Methylation-Specific PCR
Methylation-specific PCR (MSP) was used to determine the methylation status of 5 0 regulatory region of RCAN1.4 in 10 paired samples of HCC and adjacent noncancerous liver tissues using bisulphite-modified genomic DNA. In brief, 1 mg of DNA was denatured by NaOH and modified by sodium bisulphite. The DNA sample was then purified with Wizard DNA purification resin (Promega), treated again with NaOH, ethanol precipitated, and resuspended in H 2 O. Methylated and unmethylated DNA specific primer sets were used to investigate the methylation status of 5 0 regulatory region of RCAN1.4 (Supplementary Table 10 ).
Calcineurin Enzymatic Activity
The activity of calcineurin was determined using a calcineurin activity assay kit following the manufacturer's protocol. The RII phosphopeptide (Biomol, Plymouth Meeting, PA) was used as a highly specific substrate for calcineurin. The detection of free inorganic phosphate released from RII by calcineurin was based on the malachite green dye reaction. Reactions were terminated after 25 min, and absorption was read on an ultraviolet spectroscope at 620 nm. The activity was corrected for protein concentration. Calcineurin activity was expressed as a percentage compared with the control group.
Luciferase Reporter Assay
Luciferase activity was detected using the Dualluciferase reporter assay (Promega) according to the manufacturer's instructions. The cells plated in a 96-well plate were co-transfected with 150 ng of the expression plasmids, 50 ng of the promoter reporter plasmids, and 8 ng of the pRL-TK (Renila luciferase) plasmids using Lipofectamine 2000 (Invitrogen). After 6 h of transfection, the cells were washed and replaced in fresh medium. The Dual-luciferase reporter assay was performed after 48 h and the luciferase activity was normalized to the Renilla luciferase activity.
Chromatin Immunoprecipitation Assay
HCC cells of RCAN1.4 knockdown and the relative control cells (SMMC7721-shRCAN1.4 vs SMMC7721-shNC; Huh7-shRCAN1.4 vs Huh7-shNC) were cultured at w80-90% confluency. Subsequently, chromatin immunoprecipitation (ChIP) assay was performed using the EZ-ChIP TM kit (17-371; Millipore, Billerica, MA). The following antibodies were utilized to immunoprecipitate crosslinked protein-DNA complexes: rabbit anti-NFAT1 and normal rabbit IgG (12-370, Millipore). The immunoprecipitated DNA was purified for PCR analyses with primers specific for the putative binding sites within the promoter of IGF1 and VEGFA.
Bisulphite Pyrosequencing
Bisulphite-modified DNA was subjected to PCR amplification strategy using a tailed reverse primer and a biotinlabeled universal primer (Supplementary Table 10 ). PCR and sequencing primers were designed using PyroMark Assay Design 2.0 (Qiagen GmbH, Hilden, Germany), and pyrosequencing was performed using a PyroMark Q24 (Qiagen) and Pyro Gold Reagents (Qiagen). The methylation percentage of each cytosine was determined by their fluorescence intensities of cytosines, and divided by the sum of fluorescence intensity of cytosines and thymines (converted from uracil by PCR) at each CpG site. In vitro methylated DNA was included as positive control of bisulphite pyrosequencing.
Statistic Analysis
Differences among variables were assessed by c 2 analysis or two-tailed Student t test. Kaplan-Meier analysis was used to assess survival. Log-rank tests were used to compare survival of patients between subgroups. Multivariate analyses were performed by multivariate Cox proportional hazard regression model. Data were presented as mean ± SEM. Differences were considered to be statistically significant for P < .05. Transwell assays analyzed the migration (D) and invasion (E) abilities of HCC cells. *P < .05, **P < .01, ***P < .001. -0  0  TNM  I  --3 0  II  --0  III-IV  --0  Tumor differentiation  well  --24  moderate  --12  poor  --0 Abbreviations: LC, liver cirrhosis; LGDN, low grade dysplastic nodule; HGDN, high grade dysplastic nodule; eHCC, early hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; AFP, a-fetoprotein; SD, standard deviation; TNM, UICC TNM classification (6th edition). 
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